Elmiron® Lawsuit

Elmiron® has been linked to serious side effects such as eye/vision damage. 

Elmiron® linked to serious eye damage

The use of the drug Elmiron® has been linked to serious eye damage. If you have ever taken prescription Elmiron® (aka. pentosan polysulfate sodium, or PPS), you are at risk of developing a unique form of progressive eye disease. This eye damage can be (mis)diagnosed by ophthalmologists as retinal pigmentary maculopathy, pattern dystrophy, or age-related macular degeneration.

divider

Some of the common symptoms for patients experiencing this Elmiron® associated eye damage are:

• Blurred vision (often in the patient's central field of vision)
• Difficulty reading
• Dark spots in center of vision
• Straight lines that appear curved
• Muted, less vivid colors and
• Difficulty adapting to dim lighting

Call Now To Speak With A Lawyer for a Free Consultation: 1-844-275-6900

This disease is so similar in appearance to ‘ordinary’ macular degeneration that many Elmiron® patients may not even know they have this macular disorder, and instead just assume their vision is degrading. However, if you have taken Elmiron and have problems in both eyes, you may have the unique retinal injury caused by Elmiron®. In fact, a significant percentage of Elmiron® users in several studies showed Elmiron® associated retinal maculopathy and pigmentary damage. These patients had significant damage to their retina and they reported significant eye and vision problems as a result.

What is most alarming about Elmiron eye damage is that eye damage in patients can develop even after the patient has stopped taking Elmiron®. Often when a prescription drug is found to be causing a side effect, discontinuing use can reverse, or at least stop, the progression of that side effect. But in the case of Elmiron® that may not be true. It is highly recommended that if you ever took Elmiron®, you should see an ophthalmologist and have your eyes examined on a regular and on-going basis.

If you are experiencing any of the aforementioned side effects after using Elmiron, contact TheLawFirm.com today for a Free Consultation. You may be entitled to financial compensation.

Call Now To Speak With A Lawyer for a Free Consultation: 1-844-275-6900

Do you qualify for a Elmiron® lawsuit?

It is important to make sure that your ophthalmologist is aware of the current developments surrounding Elmiron. Seeing an ophthalmologist regularly will allow you to establish a baseline of the health of your retinas. This will allow you to monitor any progression of eye disease that may occur later on. This will be important for your eye health as well as to establish evidence in a lawsuit, should you choose to file one. Such a lawsuit will likely allege that Janssen Pharmaceuticals® (the maker of Elmiron®) failed to properly warn patients of known eye related injury risks. TheLawFirm.com is currently accepting cases nationally from all 50 states. Call us for a free consultation and we will help you determine if you are eligible to pursue financial compensation. It is important to act quickly because each State has a statute of limitations and the time window for pursuing a case is getting shorter each day. Our law firm works strictly on a contingency basis. This means that clients we represent only pay out of their recovery if they win their case.

Source

pubmed.ncbi.nlm.nih.gov

divider

Elmiron Lawsuit Update

May 11, 2021
Author: Daniel Gala

Elmiron MDL Court Allows Direct Filing as Cases Exceed 200

As multidistrict litigation (MDL) over the drug Elmiron continues to get underway in the District of New Jersey, the court has issued several orders that will streamline the filing of additional cases, including an order allowing plaintiffs to file their lawsuits directly with the MDL court, rather than filing their claim with a separate court first. Together, the orders should accelerate the growth of the nascent litigation, which recently surpassed 200 total cases, according to court documents.

In an order dated April 26, 2021, US District Judge Brian R. Martinotti wrote that, in order to "eliminate delays associated with transfer of cases filed in or removed from other federal district courts to this Court, and to promote judicial efficiency, any plaintiff whose case would be subject to transfer to MDL No. 2973 may file his or her case directly into MDL No. 2973 by filing in the District of New Jersey pursuant to this order."

By allowing direct filing—a standard move in multidistrict litigation—the court will make it faster and easier for new plaintiffs and their attorneys to file lawsuits that will become part of the MDL. As of May 10, the Elmiron MDL has 223 cases, court records show.

In a subsequent order issued May 5, the court initiated another important development with the release of the MDL's plaintiff and defendant fact sheets. These standardized forms allow plaintiffs and defendants to submit relevant facts to the court and opposing party in an organized, streamlined way.

The fact sheets also give a key glimpse of the evidence at issue in the fast-growing Elmiron litigation, with questions on the plaintiff fact sheet asking for information about the duration and dosage of Elmiron use, and whether or not the plaintiff ever was warned of any side effects related to taken Elmiron.

Elmiron is the brand name for pentosan polysulfate sodium (PPS), a drug used to alleviate bladder pain and discomfort, especially that caused by interstitial cystitis, also known as IC.

However, a landmark study published in 2018 revealed a connection between exposure to PPS and damage to the retina, resulting in vision problems.

"Patients reported symptoms of difficulty reading and prolonged dark adaptation despite generally intact visual acuity," the 2018 study said.

Elmiron now is forced to carry a warning regarding the potential for damage to the retina.

"Visual symptoms that have been reported include: difficulty reading, slow adjustment to low or reduced light environments, and blurred vision," the official Elmiron website warns.

With the Elmiron MDL only having been established in December 2020, the litigation still is in its very early stages. However, these recent developments are laying important foundations for later proceedings and are likely to accelerate the filing of new cases.

Stay tuned to TheLawFirm.com for the latest developments in Elmiron litigation, and if you have developed vision problems after being prescribed Elmiron for an extended period of time, contact TheLawFirm.com for a free legal consultation!

Sources:

United States District Court District of New Jersey. (Accessed 10 May 2021). Member Cases. Civil Docket For Case #: 2:20-md-02973-BRM-ESK. Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation. MDL No. 2973

United States District Court District of New Jersey. (26 April 2021). Amended Case Management Order No. # 6 (Direct Filing — Stipulated). In Re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation. Case No. 2:20-md-02973 (BRM)(ESK). MDL No. 2973

United States District Court District of New Jersey. (5 May 2021). Amended Case Management Order No. # 8 (Plaintiff Fact Sheets and Defendants' Fact Sheets. In Re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation. Case No. 2:20-md-02973 (BRM)(ESK). MDL No. 2973

Pearce, William A. et al. Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium. Ophthalmology. (November 2018).

Janssen Pharmaceuticals, Inc. (2020). Elmiron (pentosan polysulfate sodium) Official Website

Call Now To Speak With A Lawyer for a Free Consultation: 1-844-275-6900

Do you qualify for a Elmiron® lawsuit?

IMPORTANT!
There are NO FEES unless we win your case!
SEE OUR NO RECOVERY, NO FEE - GUARANTEE!

Legal Disclaimer: The information in this article is not intended to be used as medical information or diagnosis. The sources of the information presented in the article have been researched and are linked within the article. Please seek out medical advice from a licensed medical professional if you are experiencing a problem with any of the drugs or devices mentioned in this article.